Neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma: does everyone need it?

Neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma: does everyone need it?

Автор: Chichevatov D.A., Sinev E.N., Glukhov A.E., Seliverstova O.M.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Клинические исследования

Статья в выпуске: 2 т.23, 2024 года.

Бесплатный доступ

Objective. In accordance with clinical guidelines, neoadjuvant chemoradiotherapy (nCRT) is recommended as a beneficial option for treatment of thoracic esophageal squamous cell carcinoma (TESCC). However, some studies did not demonstrate potential benefits of nCRT. In this paper we compared treatment outcomes of surgery alone with preoperative CRT followed by surgery. Material and Methods Group 1 (n=147) consisted of patients who underwent surgery alone. Group 2 (n=3,337) was formed in the framework of the present systematic review and meta-analysis (15 publications captured 20 separate subgroups for analysis). Patients of group 2 received nCRT followed by esophagectomy. Overall survival (OS) and median OS were estimated.

Еще

Squamous cell esophageal carcinoma, chemoradiation therapy, surgery

Короткий адрес: https://sciup.org/140305905

IDR: 140305905   |   DOI: 10.21294/1814-4861-2024-23-2-15-25

Список литературы Neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma: does everyone need it?

  • Alves I.P.F., Tercioti Junior V., Coelho Neto J.S., Ferrer J.A.P., Carvalheira J.B.C., Pereira E.B., Lopes L.R., Andreollo N.A. Neoadjuvant chemoradiotherapy followed by transhital esophagectomy in locally advanced esophageal squamous cell carcinoma: impact of pathological complete response. Arq Bras Cir Dig. 2022; 34(3). https://doi.org/10.1590/0102-672020210002e1621.
  • Chen D., Wang W., Mo J., Ren Q., Miao H., Chen Y., Wen Z. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments. BMC Cancer. 2021; 21(1): 145. https://doi.org/10.1186/s12885-021-07867-9.
  • Chen H.S., Hsu P.K., Liu C.C., Wu S.C. Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma. Sci Rep. 2018; 8(1): 2180. https://doi.org/10.1038/s41598-018-20654-0.
  • Fan Y., Jiang Y., Zhou X., Chen Q., Huang Z., Xu Y., Gong L., Yu H., Yang H., Liu J., Lei T., Zhao Q., Mao W. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget. 2016; 7(31): 50624-34. https://doi.org/10.18632/oncotarget.9562.
  • Hsu P.K., Chien L.I., Huang C.S., Hsieh C.C., Wu Y.C., Hsu W.H., Chou T.Y. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all? Interact Cardiovasc Thorac Surg. 2013; 17(3): 460-6. https://doi.org/10.1093/icvts/ivt216.
  • Li C.Y., Huang P.M., Chu P.Y., Chen P.M., Lin M.W., Kuo S.W., Lee J.M. Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols. Biomed Res Int. 2016. https://doi.org/10.1155/2016/6423297.
  • Li X., Luan S., Yang Y., Zhou J., Shang Q., Fang P., Xiao X., Zhang H., Yuan Y. Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery. Cancers (Basel). 2022; 14(15): 3721. https://doi.org/10.3390/cancers14153721.
  • Malthaner R.A., Yu E., Sanatani M., Lewis D., Warner A., Dar A.R., Yaremko B.P., Bierer J., PalmaDA., FortinD., InculetR.I., Frechette E., Raphael J., Gaede S., Kuruvilla S., Younus J., Vincent M.D., Rodrigues G.B. The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial. Thorac Cancer. 2022; 13(13): 1898-915. https://doi.org/10.1111/1759-7714.14433.
  • Miller J.A., Groman A., Yendamuri S., Hennon M. Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer. J Surg Res. 2019; 236: 259-65. https://doi.org/10.1016/j.jss.2018.11.052.
  • MunchS., Pigorsch S. U., FeithM., Slotta-Huspenina J., Weichert W., Friess H., Combs S.E., Habermehl D. Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol. 2017; 12(1): 182. https://doi.org/10.1186/s13014-017-0904-y.
  • Nagaki Y., Motoyama S., Sato Y., Wakita A., Fujita H., Sasaki Y., Imai K., Minamiya Y. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy. BMC Cancer. 2021; 21(1): 1192. https://doi.org/10.1186/s12885-021-08918-x.
  • Wang X., Wang H., Wang H., Huang J., Wang X., Jiang Z., Tan L., Jiang D., Hou Y. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery. BMC Cancer. 2021; 21(1): 111. https://doi.org/10.1186/s12885-020-07779-0.
  • Wu Y.H., Lin M.Q., Wang Z.P., Li J.C. Clinical significance of risk stratification of esophageal squamous cell carcinoma after neoadjuvant chemoradiation and surgery. Transl Oncol. 2021; 14(5): 101037. https://doi.org/10.1016/j.tranon.2021.101037.
  • Xiao X., Cheng C., Cheng L., Shang Q.X., Yang Y.S., Zeng X.X., Hu Y., Chen L.Q., Yuan Y. Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer. Ann Surg Oncol. 2023; 30(2): 886-96. https://doi.org/10.1245/s10434-022-12758-9.
  • Zhang C., Xu F., Qiang Y., Cong Z.Z., Wang Q., Zhang Z., Luo C., Qiu B.M., Hu L.W., Shen Y. Prognostic significance of tumor regression grade in esophageal squamous cell carcinoma after neoadjuvant chemoradiation. Front Surg. 2023; 9: 1029575. https://doi.org/10.3389/fsurg.2022.1029575.
  • Tu C.C., Hsu P.K., Chien L.I., Liu W.C., Huang C.S., Hsieh C.C., Hsu H.S., Wu Y.C. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer. 2017; 17(1): 62. https://doi.org/10.1186/s12885-017-3063-5.
  • Wiesel O., Zlotnik O., Morgenstern S., Tsur M., Menasherov N., Feferman Y., Ben-Aharon I., Kashtan H. Predicting Factors for a Favorable Pathologic Response to Neoadjuvant Therapy in Esophageal Cancer. Am J Clin Oncol. 2022; 45(12): 514-8. https://doi.org/10.1097/COC.0000000000000954.
  • Liu N., Zhou Y., Lee J.J. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021; 21(1): 111. https://doi.org/10.1186/s12874-021-01308-8.
  • Haj Mohammad N., Hulshof M.C., Bergman J.J., Geijsen D., Wilmink J.W., van Berge Henegouwen M.I., van Laarhoven H.W. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC Cancer. 2014; 14: 56. https://doi.org/10.1186/1471-2407-14-56.
  • Ristau J., Thiel M, Katayama S., Schlampp I., Lang K., Hafner M.F., Herfarth K., Debus J., Koerber S.A. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol. 2021; 16(1): 23. https://doi.org/10.1186/s13014-021-01749-x.
  • Yang H., Liu H., Chen Y., Zhu C., Fang W., Yu Z., Mao W., Xiang J., Han Y., Chen Z., Yang H., Wang J., Pang Q., Zheng X., Yang H., Li T., Lordick F., D'Journo X.B., Cerfolio R.J., Korst R.J., Novoa N.M., Swanson S.J., Brunelli A., Ismail M., Fernando H.C., Zhang X., Li Q., Wang G., Chen B., Mao T., Kong M., Guo X., Lin T., Liu M., Fu J.; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018; 36(27): 2796-803. https://doi.org/10.1200/JCO.2018.79.1483.
  • Tang H., Wang H., Fang Y., Zhu J.Y., Yin J., Shen Y.X., Zeng Z.C., Jiang D.X., Hou Y.Y., Du M., Lian C.H., Zhao Q., Jiang H.J., Gong L., Li Z.G., Liu J., Xie D.Y., Li W.F., Chen C., Zheng B., Chen K.N., Dai L., Liao Y.D., Li K., Li H.C., Zhao N.Q., Tan L.J. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol. 2023; 34(2): 163-72. https://doi.org/10.1016/j.annonc.2022.10.508.
  • Kumar T., Pai E., Singh R., Francis N.J., Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol. 2020; 18(1): 59. https://doi.org/10.1186/s12957-020-01830-x.
  • Merritt R.E., Kneuertz P.J., Abdel-Rasoul M., D'Souza D.M., Perry K.A. Comparative analysis of long-term oncologic outcomes for minimally invasive and open Ivor Lewis esophagectomy after neoadjuvant chemoradiation: a propensity score matched observational study. J Cardio-thorac Surg. 2021; 16(1): 347. https://doi.org/10.1186/s13019-021-01728-z.
  • Wang C., Zhao K., Hu S., Huang Y., Ma L., Song Y., Li M. A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR. BMC Cancer. 2020; 20(1): 544. https://doi.org/10.1186/s12885-020-07040-8.
  • Okamura A., Watanabe M., Okui J., Matsuda S., Takemura R., Kawakubo H., Takeuchi H., Muto M., Kakeji Yo., Kitagawa Yu., Doki Yu. Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan. Ann Surg Oncol. 2023; 30: 2176-85. https://doi.org/10.1245/s10434-022-12960-9.
  • Huang R.W., Chao Y.K., Wen Y.W., Chang H.K., Tseng C.K., Chan S.C., Liu Y.H. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol. 2014; 12: 170. https://doi.org/10.1186/1477-7819-12-170.
  • An L., Li M., Jia Q. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma. Mol Cancer. 2023; 22(1): 140. https://doi.org/10.1186/s12943-023-01839-2.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp